A multicentric, single blind, parallel, randomized, phase-III study to evaluate the immunogenicity and safety of BEs combined pentavalent DTwP-rHepB-HIB liquid vaccine administered to 6-8 week old healthy Indian subjects at 6-10-14 weeks EPI schedule in comparison with marketed Shan5 vaccine.

Trial Profile

A multicentric, single blind, parallel, randomized, phase-III study to evaluate the immunogenicity and safety of BEs combined pentavalent DTwP-rHepB-HIB liquid vaccine administered to 6-8 week old healthy Indian subjects at 6-10-14 weeks EPI schedule in comparison with marketed Shan5 vaccine.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Biological E Limited
  • Most Recent Events

    • 21 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top